Progyny Inc at Barclays Global Healthcare Conference Transcript
All right. Thanks, everybody, for joining us today. We're happy to be hosting Progyny. And to my right, I have Pete Anevski, the CEO. For anyone that doesn't know me, my name is Peter Warendorf, I cover Progyny here at Barclays, as well as some of the other tech and distribution names.
So Pete, maybe to kick off the conversation, so there was strength in 4Q. It seems like you guys came in ahead of guidance, maybe utilization was more stable. Can you give us a quick recap of the quarter, any highlights you think are worth mentioning?
I know there was some nuance around membership that we'll dive into in a minute, and there was growth of around 20% in 2025 ex the one customer. Would you -- how would you characterize where the business is at more generally?
Questions & Answers
Sure. Hello, everybody, by the way, and thank you for joining us. So the business is in really good shape. As you mentioned, Peter, the -- we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
